We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biomarkers Identify Pregnant Women with Lupus or APL at Risk for Adverse Outcomes

By LabMedica International staff writers
Posted on 07 Oct 2015
Print article
A consortium of researchers has found that testing blood of pregnant women with systemic lupus erythematosus (SLE) or antiphospholipid antibodies (APL) for certain biomarkers can identify and stratify low- vs. high-risk patients early in pregnancy.

"Given that over 20% of pregnant women with lupus APL experience adverse pregnancy outcomes, the ability to identify patients early in pregnancy, who are destined for poor outcomes, would significantly impact care," said lead investigator Jane E. Salmon, MD, Weill Cornell Medical College (New York City, NY, USA).

The investigators used data and samples from the PROMISSE Study, where 497 pregnant patients with SLE and/or APL were enrolled at <12 weeks gestation between September 2003 and August 2013 at seven sites, along with 207 matched healthy controls, and were followed every month of pregnancy. They found that maternal-blood biomarkers, specifically – circulating angiogenic factors that regulate development of the placenta and influence the health of blood vessels in the mother, can be assessed early in pregnancy. As early as 12-15 weeks into pregnancy, changes in these biomarkers can signal an increased risk for severe complications.

The researchers also found that measuring these biomarkers had a high negative predictive value, therefore severe complications could be ruled out in most patients. "Timely risk stratification of patients is important for effective clinical care and optimal allocation of healthcare resources," said Dr. Salmon. Without good predictive tests, most of these patients undergo extensive antenatal evaluation, including serial obstetrical ultrasound exams and multiple visits to rheumatologists and obstetricians. With good predictive tests, the majority would be identified as being at low risk and the number of their medical visits and healthcare costs could be substantially reduced. Those at high risk would be managed by specialists with close monitoring and delivery.

"Pregnancies in patients with SLE and/or APL can result in poor outcomes even when disease activity is low, and baseline clinical features and laboratory tests have only modest ability to identify patients at highest risk," said Dr. Salmon, "Our study is the first to demonstrate, in a prospective cohort, the usefulness of angiogenic biomarkers measured as early as the 12th week of pregnancy, in combination with clinical criteria, to identify patients with SLE and/or APL at risk of severe adverse pregnancy outcomes."

The study, by Kim MY et al, was published online ahead of print September 28, 2015, in the American Journal of Obstetrics & Gynecology.

Related Links:

Weill Cornell Medical College



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.